About antimicrobial

Covid 19

Previously, Biocote® had obtained studies of the H1N1 swine flu virus using the facilities at a local university and received positive results on the effectiveness of BioCote® technology against this virus.

In order to confirm further viral efficacy of BioCote® technology, BioCote® commissioned antiviral testing through a third-party laboratory using a BioCote® treated product against a strain of the coronavirus family. In this particular case, the tests were done with feline coronavirus, strain Munich to obtain additional information of the effectiveness. After testing to the BS ISO 21702:2019 standard, the polypropylene containing BioCote® technology was proven effective against feline coronavirus, strain Munich, with a reduction of 90% in 2 hours.

This data does not show efficacy against the current pandemic strain of SARS-CoV-2. To confirm whether the virulence properties of SARS-CoV-2 (COVID-19) are affected by BioCote® technology, the testing will need to be repeated on the actual SARS-CoV-2 (COVID-19) strain. The Centers for Disease Control and Prevention (CDC) have categorised the virus at biohazard level 3 and above, meaning the SARS-CoV-2 (COVID-19) virus will not be available for public commercial testing at this point in the pandemic.